Clinical Indications for Hyperbaric Oxygen Therapy

Hyperbaric medicine consultation may be appropriate when severe anemia is accompanied by evidence of inadequate tissue oxygen delivery and red blood cell transfusion is unavailable or cannot be performed.

Situations may include:

• Severe acute blood loss when compatible blood is unavailable
• Inability to crossmatch blood
• Severe hemolytic anemia in which transfusion is problematic
• Patient refusal of blood products
• Critically low hemoglobin with evidence of organ dysfunction
• Persistent tissue hypoxia despite conventional supportive treatment

Consultation should be based on the overall clinical picture rather than a single hemoglobin threshold.

Signs of myocardial ischemia, neurologic dysfunction, lactic acidosis, hemodynamic instability, or progressive organ dysfunction may indicate that compensatory mechanisms are failing.

HBOT as Part of Critical Care

HBOT does not correct the underlying cause of anemia.

Treatment should occur alongside comprehensive critical-care management, which may include:

• Control of active bleeding
• Surgical or endovascular intervention
• Volume resuscitation
• Iron supplementation
• Folate and vitamin B12 when indicated
• Erythropoiesis-stimulating therapy in selected patients
• Reduction of unnecessary blood sampling
• Optimization of cardiac and respiratory function
• Correction of coagulopathy
• Treatment of the underlying disease process

Patients with severe anemia may be critically ill, making coordination between hyperbaric medicine, critical care, surgery, hematology, anesthesia, and other specialists essential.

Clinical Evidence and Guidelines

Severe anemia is recognized by the Undersea & Hyperbaric Medical Society as an accepted indication for HBOT when critically reduced red blood cell mass compromises oxygen delivery and transfusion is not possible.

The physiologic basis for treatment is well established: increasing ambient pressure allows substantially greater amounts of oxygen to dissolve directly in plasma, partially compensating for the loss of hemoglobin-mediated oxygen transport.

The clinical evidence consists primarily of physiologic studies, animal research, case reports, case series, and accumulated clinical experience rather than large randomized trials.

A systematic review of published severe-anemia cases found favorable outcomes reported with adjunctive HBOT, particularly in patients who could not receive transfusion.

More recent reviews continue to describe HBOT as a potential bridge therapy for critically anemic patients when transfusion is unavailable or unacceptable.

Medicare Coverage

Although severe anemia is recognized by UHMS as an indication for HBOT, current Medicare National Coverage Determination 20.29 specifically lists exceptional blood loss anemia as a noncovered condition.

This distinction is important because UHMS clinical indications and Medicare coverage criteria are not identical.

Commercial payer policies may also vary. Coverage and authorization requirements should therefore be reviewed individually before treatment when circumstances permit.

When to Refer

Consider hyperbaric medicine consultation when a patient has severe, clinically significant anemia with evidence of compromised oxygen delivery and transfusion cannot be performed or is not immediately available.

Particular concern is warranted when there is:

• Hemodynamic instability
• Myocardial ischemia
• Altered mental status
• Severe metabolic acidosis
• Elevated lactate
• Progressive organ dysfunction
• Critically reduced hemoglobin with ongoing symptoms
• Continued deterioration despite conventional supportive care

HBOT should be considered a bridge to definitive management, not a replacement for hemorrhage control, transfusion when appropriate, or treatment of the underlying cause of anemia.